Autolus Therapeutics PLC (AUTL)
3.08
+0.07
(+2.33%)
USD |
NASDAQ |
Nov 15, 16:00
3.08
0.00 (0.00%)
After-Hours: 20:00
Autolus Therapeutics Research and Development Expense (TTM): 129.68M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 129.68M |
| March 31, 2024 | 126.30M |
| December 31, 2023 | 123.02M |
| September 30, 2023 | 105.40M |
| June 30, 2023 | 105.80M |
| March 31, 2023 | 110.78M |
| December 31, 2022 | 117.36M |
| September 30, 2022 | 125.49M |
| June 30, 2022 | 120.15M |
| March 31, 2022 | 114.07M |
| Date | Value |
|---|---|
| December 31, 2021 | 110.84M |
| September 30, 2021 | 133.88M |
| June 30, 2021 | 135.14M |
| March 31, 2021 | 134.33M |
| December 31, 2020 | 134.89M |
| September 30, 2020 | 125.53M |
| June 30, 2020 | 119.29M |
| March 31, 2020 | 114.14M |
| December 31, 2019 | 105.42M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
105.40M
Minimum
Sep 2023
135.14M
Maximum
Jun 2021
120.61M
Average
120.15M
Median
Jun 2022
Research and Development Expense (TTM) Benchmarks
| Adaptimmune Therapeutics PLC | 143.17M |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | 35.08M |
| TC BioPharm (Holdings) PLC | -- |
| Bicycle Therapeutics PLC | 167.88M |